Myelofibrosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The myelofibrosis treatment market size is expected to grow from USD 1.45 billion in 2025 to USD 1.57 billion in 2026 and is forecast to reach USD 2.38 billion by 2031 at 8.68% CAGR over 2026-2031. This report is segmented by Disease Type (Primary, Secondary MF), Drug Class (Targeted Therapy, Chemotherapy, Immunomodulatory Agents, Others), Route of Administration (Oral, Intravenous, Subcutaneous, Others), End User (Hospitals, Specialty Clinics, Ambulatory Centers, Academic Centers, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Myelofibrosis Treatment Market Trends and Insights

Increasing Adoption of Phenotype-Specific JAK Inhibitor Therapy

Treatment selection in the myelofibrosis treatment market is shifting toward a phenotype-based approach. Anemia severity, platelet count, and treatment history increasingly guide therapy selection. Momelotinib inhibits JAK1, JAK2, and ACVR1, lowering hepcidin levels, supporting erythropoiesis, and addressing splenomegaly. Published treatment guidance positions pacritinib for patients with platelet counts below 50 × 10⁹/L and momelotinib for transfusion-dependent patients, creating clearer clinical roles for approved JAK inhibitors.

Pipeline Expansion of Disease-Modifying and Combination Therapies

Combination therapy programs are expanding options in the myelofibrosis treatment market. In the 2025 MANIFEST-2 trial, pelabresib plus ruxolitinib achieved SVR35 in 65.9% of JAK inhibitor-naive patients, compared with 35.2% for ruxolitinib alone. Selinexor plus ruxolitinib achieved SVR35 in 47% of patients at week 36, compared with 23% in the comparator group. Karyopharm submitted a supplemental New Drug Application for the combination in August 2026 and sought accelerated approval. Imetelstat showed a median overall survival of 30.7 months versus 15.4 months with best-available therapy in an updated post-hoc matched analysis presented at ASCO 2026. These programs cover BET inhibition, XPO1 blockade, MDM2 activation, telomerase inhibition, and Type II JAK2 selectivity for frontline and later-line care.

Treatment-Limiting Anemia, Thrombocytopenia, and Myelosuppression

Myelosuppression remains a key safety challenge in JAK inhibitor treatment and can limit dose escalation for patients requiring more intensive therapy. In MANIFEST-2, 52.8% of patients receiving pelabresib plus ruxolitinib experienced thrombocytopenia, while 44.8% experienced anemia of any grade. In the SENTRY trial, thrombocytopenia occurred in 59% of the selinexor plus ruxolitinib group, compared with 43% of the ruxolitinib plus placebo group. Dose reductions to manage hematologic toxicity can reduce JAK inhibitor effectiveness, limiting broader adoption of certain combination therapies.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Anemia-Directed Treatment Options
• Growing Demand for Post-JAK Inhibitor Treatment
• High Treatment Cost and Unequal Reimbursement Access

Segment Analysis

Primary myelofibrosis held 55.67% of the myelofibrosis treatment market share by disease type in 2025, driven by higher de novo incidence than post-essential thrombocythemia and post-polycythemia vera forms. It also remains the established focus of diagnosis and initial treatment. Secondary myelofibrosis is forecast to grow at a 9.22% CAGR through 2031 as longer survival among patients with essential thrombocythemia and polycythemia vera increases the population at risk of transformation. Hydroxyurea and pegylated interferon support long-term disease management, increasing the need for transformation monitoring.

Advances in molecular diagnosis and risk classification support the secondary myelofibrosis segment. A 2026 study from an Indian tertiary referral cohort found that upfront 69-gene next-generation sequencing reclassified 16.4% of patients with myeloproliferative neoplasms into higher prognostic risk categories. The MYSEC-PM score supports risk-based therapy selection for post-myeloproliferative neoplasm secondary myelofibrosis and is used in European treatment algorithms, with increasing adoption across Asia-Pacific specialty centers. These tools improve referral, molecular testing, and timely therapeutic review.

Targeted drug therapy held 58.66% of drug-class revenue in 2025 and includes JAK inhibitors and other molecularly targeted agents. Four approved JAK inhibitors supported the category, while ruxolitinib remained central to front-line symptom and spleen management. The segment reflects a growing focus on matching treatment with anemia and platelet profiles. Emerging targeted combinations are generally being evaluated alongside, rather than in place of, ruxolitinib.

Chemotherapy is forecast to grow at an 8.80% CAGR through 2031, the highest among drug classes. Its use is linked to cytoreductive treatment, particularly hydroxyurea for lower-risk patients in reimbursement-constrained areas of the Asia-Pacific and South America. Pegylated interferon plus ruxolitinib improved marrow cellularity and fibrosis in patients intolerant of prior JAK inhibitor therapy. The Others category includes telomerase inhibitors and MDM2 inhibitors awaiting approval, which could expand the category as Phase 3 programs report results.

Complete Report Scope:

• By Disease Type
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
• By Drug Class
  • Targeted Drug Therapy
    • JAK Inhibitors
    • Other Targeted Therapy
  • Chemotherapy
  • Immunomodulatory Agents
  • Others
• By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Other Routes of Administration
• By End User
  • Hospitals
  • Specialty Hematology and Oncology Clinics
  • Ambulatory Infusion Centers
  • Academic Medical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.80% of the myelofibrosis treatment market share in 2025, supported by an estimated 20,000 patients in the United States and access to all four FDA-approved JAK inhibitors. Restricted specialty pharmacies support treatment distribution and monitoring. Europe is the second-largest regional market, with ruxolitinib, momelotinib, and fedratinib authorized through the European Medicines Agency’s centralized route. Germany, the United Kingdom, and France lead regional volumes through designated myeloproliferative neoplasm expert centers, while country-specific reimbursement often requires clinical and health economic evidence.

Asia-Pacific is forecast to grow at an 8.95% CAGR through 2031. China’s National Medical Products Administration approved TQ05105, branded Anxu, on February 28, 2026, as a dual JAK/ROCK inhibitor for eligible adults with primary and secondary myelofibrosis; registration data showed SVR35 in 58.33% of patients and TSS50 in 77.78% of patients. China’s myelofibrosis patient population exceeded 67,000 in 2025 and is projected to approach 300,000 by 2030, supported by diagnostic capacity, aging demographics, and tertiary hematology infrastructure. Japan supports steady JAK inhibitor use, while India’s 2026 69-gene sequencing study reclassified 16.4% of patients into higher prognostic risk groups, supporting earlier specialist care.

The Middle East and Africa remain at an early commercial stage for JAK inhibitor therapy, with treatment concentrated in tertiary oncology centers across GCC countries, South Africa, and other major urban locations. Limited reimbursement infrastructure requires many patients to rely on hospital formularies or manufacturer support programs. Brazil and Argentina lead South American activity, although cost and access constraints persist, while Brazil’s public health system is beginning to incorporate treatment pathways as awareness expands beyond academic centers. Diagnostic expansion, international trial participation, and stronger specialist referral networks support gradual adoption across both regions.

List of Companies Covered in this Report:

• Abbvie
• Bristol-Myers Squibb
• Geron Corporation
• GlaxoSmithKline
• Incyte
• Kartos Therapeutics, Inc.
• Karyopharm Therapeutics
• MorphoSys AG
• Novartis
• PharmaEssentia Corporation
• Swedish Orphan Biovitrum AB (publ)
• Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support